AR031341A1 - Uso de cci-779 como agente antineoplastico - Google Patents

Uso de cci-779 como agente antineoplastico

Info

Publication number
AR031341A1
AR031341A1 ARP010105310A ARP010105310A AR031341A1 AR 031341 A1 AR031341 A1 AR 031341A1 AR P010105310 A ARP010105310 A AR P010105310A AR P010105310 A ARP010105310 A AR P010105310A AR 031341 A1 AR031341 A1 AR 031341A1
Authority
AR
Argentina
Prior art keywords
cci
antineoplastic agent
neoplasms
rapamycin
hydroxymethyl
Prior art date
Application number
ARP010105310A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR031341A1 publication Critical patent/AR031341A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de CCI-779 para el tratamiento de neoplasmas, siendo CCI-779 el 42-éster de rapamicina con ácido 3-hidroxi-2-(hidroximetil)-metil propionico.
ARP010105310A 2000-11-15 2001-11-14 Uso de cci-779 como agente antineoplastico AR031341A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24907700P 2000-11-15 2000-11-15

Publications (1)

Publication Number Publication Date
AR031341A1 true AR031341A1 (es) 2003-09-17

Family

ID=22941961

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105310A AR031341A1 (es) 2000-11-15 2001-11-14 Uso de cci-779 como agente antineoplastico

Country Status (28)

Country Link
US (3) US20020091137A1 (es)
EP (1) EP1335725B1 (es)
JP (4) JP4472251B2 (es)
KR (1) KR100827942B1 (es)
CN (2) CN102058588A (es)
AR (1) AR031341A1 (es)
AT (1) ATE393629T1 (es)
AU (2) AU2731302A (es)
BR (1) BR0115323A (es)
CA (1) CA2429020C (es)
CY (1) CY1108109T1 (es)
DE (1) DE60133831T2 (es)
DK (1) DK1335725T3 (es)
EA (1) EA007096B1 (es)
ES (1) ES2305134T3 (es)
HK (1) HK1058008A1 (es)
HU (1) HUP0400521A3 (es)
IL (2) IL155871A0 (es)
MX (1) MXPA03004192A (es)
NO (1) NO20032181L (es)
NZ (1) NZ539668A (es)
PL (1) PL207061B1 (es)
PT (1) PT1335725E (es)
SG (1) SG148031A1 (es)
SI (1) SI1335725T1 (es)
TW (1) TWI286074B (es)
WO (1) WO2002040000A2 (es)
ZA (1) ZA200304603B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
ES2705016T3 (es) 2001-02-19 2019-03-21 Novartis Int Pharmaceutical Ag Derivado de rapamicina para el tratamiento de cáncer de pulmón
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
CA2472341C (en) * 2002-02-01 2011-06-21 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
JP2005531391A (ja) * 2002-06-27 2005-10-20 微創医療器械（上海）有限公司 薬剤放出ステント
CN100402031C (zh) 2002-07-30 2008-07-16 惠氏公司 含有瑞帕霉素羟基酯的胃肠外制剂
DE60324609D1 (de) * 2002-09-17 2008-12-18 Wyeth Corp GRANULIERTE FORMULIERUNG DES RAPAMYCINESTERS CCl-779
BR0316111A (pt) 2002-11-21 2005-09-13 Wyeth Corp Métodos para diagnosticar rcc e outros tumores sólidos
EP1592811A2 (en) * 2003-02-11 2005-11-09 Wyeth Methods for monitoring drug activities in vivo
US7643943B2 (en) 2003-02-11 2010-01-05 Wyeth Llc Methods for monitoring drug activities in vivo
US20050287532A9 (en) * 2003-02-11 2005-12-29 Burczynski Michael E Methods for monitoring drug activities in vivo
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
WO2004097052A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for prognosis and treatment of solid tumors
WO2005011688A1 (en) * 2003-07-25 2005-02-10 Wyeth Cci-779 lyophilized formulations
AR046194A1 (es) * 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
CN101155579B (zh) 2005-02-03 2012-10-31 综合医院公司 治疗吉非替尼耐药性癌症的方法
CA2596392A1 (en) * 2005-02-15 2006-08-24 Wyeth Orally bioavailable cci-779 tablet formulations
CN103110948A (zh) * 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
ES2481671T3 (es) * 2005-11-21 2014-07-31 Novartis Ag Inhibidores de mTOR en el tratamiento de tumores endocrinos
AU2006331874A1 (en) * 2005-12-20 2007-07-05 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
DE102006011507A1 (de) * 2006-03-14 2007-09-20 Lts Lohmann Therapie-Systeme Ag Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US20090076060A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched temsirolimus
EP2198554B1 (en) * 2007-10-03 2016-03-23 Genesis Technical Systems, Corp. Dynamic, asymmetric rings
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
AU2013205002B2 (en) * 2008-03-21 2016-09-15 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
WO2010132233A1 (en) * 2009-05-13 2010-11-18 The Trustees Of The University Of Pennsylvania Combination antineoplastic therapy
JP2013527223A (ja) * 2010-06-02 2013-06-27 フレゼニウス・カビ・オンコロジー・リミテッド ラパマイシンエステルの安定な医薬組成物
US9745941B2 (en) * 2014-04-29 2017-08-29 Ford Global Technologies, Llc Tunable starter resistor
CA2992629C (en) * 2015-08-24 2020-06-30 Shanxi Yabao Health Products Co., Ltd. Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN111110676A (zh) * 2020-03-07 2020-05-08 天津医科大学总医院 阿帕替尼及联合cci-779在制备肺癌药物中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
EP0525960B1 (en) 1991-06-18 1996-03-20 American Home Products Corporation Use of rapamycin for the treatment of adult T-cell leukemia/lymphoma
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
DK1318837T3 (da) 2000-08-11 2005-01-10 Wyeth Corp Fremgangsmåde til behandling af östrogenreceptorpositivt carcinom
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI233359B (en) 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
TWI296196B (en) 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569

Also Published As

Publication number Publication date
NZ539668A (en) 2007-06-29
KR20040029309A (ko) 2004-04-06
DE60133831D1 (de) 2008-06-12
PT1335725E (pt) 2008-06-19
EA007096B1 (ru) 2006-06-30
CN102058588A (zh) 2011-05-18
KR100827942B1 (ko) 2008-05-13
CA2429020C (en) 2009-05-26
US7189735B2 (en) 2007-03-13
EA200300566A1 (ru) 2003-10-30
PL207061B1 (pl) 2010-10-29
NO20032181D0 (no) 2003-05-14
HUP0400521A3 (en) 2007-05-29
CY1108109T1 (el) 2014-02-12
ZA200304603B (en) 2004-09-13
SG148031A1 (en) 2008-12-31
TWI286074B (en) 2007-09-01
EP1335725A2 (en) 2003-08-20
US20070142425A1 (en) 2007-06-21
SI1335725T1 (sl) 2008-08-31
DK1335725T3 (da) 2008-06-30
MXPA03004192A (es) 2003-09-22
NO20032181L (no) 2003-05-14
HK1058008A1 (en) 2004-04-30
JP2004517065A (ja) 2004-06-10
IL155871A (en) 2012-03-29
PL362740A1 (en) 2004-11-02
AU2007201324A1 (en) 2007-04-19
US20030153593A1 (en) 2003-08-14
CA2429020A1 (en) 2002-05-23
BR0115323A (pt) 2004-02-17
AU2007201324B2 (en) 2010-11-18
WO2002040000A2 (en) 2002-05-23
EP1335725B1 (en) 2008-04-30
JP2016094444A (ja) 2016-05-26
JP2010018620A (ja) 2010-01-28
IL155871A0 (en) 2003-12-23
US20020091137A1 (en) 2002-07-11
AU2731302A (en) 2002-05-27
ES2305134T3 (es) 2008-11-01
ATE393629T1 (de) 2008-05-15
JP4472251B2 (ja) 2010-06-02
JP2014088430A (ja) 2014-05-15
US7781446B2 (en) 2010-08-24
DE60133831T2 (de) 2009-05-20
WO2002040000A3 (en) 2002-09-06
HUP0400521A2 (hu) 2004-06-28
CN1678312A (zh) 2005-10-05

Similar Documents

Publication Publication Date Title
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
DK1635830T3 (da) Granulatformulering af rapamycinesteren CCI-779
AR043403A1 (es) Combinaciones antineoplasticas
NO20050455L (no) Parenterale formuleringer inneholdende en rapamycinhydroksyester
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
AR051664A1 (es) Agente contra la demodicosis
PE20080138A1 (es) Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos
AR034071A1 (es) Combinaciones antineoplasicas
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
BR0213019B1 (pt) formulaÇço para uso na neutralizaÇço de pelo menos uma substÂncias tàxica.
GT200600044A (es) Polimorfo cci-779 y su uso
PA8577601A1 (es) Derivados aldehido de polietilenglicol
NO20062271L (no) CCI-779 for behandling av mantle celle lymfom
AR008860A1 (es) Empleo de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica
AR005704A1 (es) Heteroariloxazolidinonas
ES1047068Y (es) Juego de cuerpos lastrados para el tratamiento de la incontinencia urinaria.
ECSP961762A (es) Compuestos antibacterianos
ES1044150Y (es) Dispositivo para montaje de mesas.
ECSP003536A (es) Derivados de rufomicina utiles como antibioticos
ECSP982594A (es) Oxazolidinonas triciclicamente sustituidas
ECSP972021A (es) Nuevas oxazolidinonas substituidas
ECSP993064A (es) Compuestos organicos

Legal Events

Date Code Title Description
FB Suspension of granting procedure